Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,006 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Gay F, Günther A, Offidani M, Engelhardt M, Salvini M, Montefusco V, Patriarca F, Aquino S, Pönisch W, Spada S, Schub N, Gentili S, Wäsch R, Corradini P, Straka C, Palumbo A, Einsele H, Boccadoro M, Sonneveld P, Gramatzki M. Gay F, et al. Among authors: palumbo a. Cancer. 2021 Sep 15;127(18):3413-3421. doi: 10.1002/cncr.33647. Epub 2021 Jun 28. Cancer. 2021. PMID: 34181755 Free article. Clinical Trial.
Lenalidomide: a new therapy for multiple myeloma.
Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H. Palumbo A, et al. Cancer Treat Rev. 2008 May;34(3):283-91. doi: 10.1016/j.ctrv.2007.12.005. Epub 2008 Jan 29. Cancer Treat Rev. 2008. PMID: 18230411 Review.
Management of older patients with multiple myeloma.
Gay F, Palumbo A. Gay F, et al. Among authors: palumbo a. Blood Rev. 2011 Mar;25(2):65-73. doi: 10.1016/j.blre.2010.10.003. Epub 2011 Feb 4. Blood Rev. 2011. PMID: 21295387 Review.
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, Vitolo U, Palumbo A. Benevolo G, et al. Among authors: palumbo a. Cancer. 2011 May 1;117(9):1884-90. doi: 10.1002/cncr.25743. Epub 2010 Nov 18. Cancer. 2011. PMID: 21509765 Free article. Clinical Trial.
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, Gentilini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A. Bringhen S, et al. Among authors: palumbo a. Blood. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759. Epub 2014 May 22. Blood. 2014. PMID: 24855212 Free article. Clinical Trial.
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.
Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M. Bringhen S, et al. Among authors: palumbo a. Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16. Leukemia. 2018. PMID: 29263440 Free article. Clinical Trial.
Stem Cell Transplantation in Multiple Myeloma.
Offidani M, Gentili S, Gay F, Aghemo E, Maracci L, Corvatta L, Palumbo A. Offidani M, et al. Among authors: palumbo a. Curr Cancer Drug Targets. 2017;17(9):769-781. doi: 10.2174/1568009616666160920090236. Curr Cancer Drug Targets. 2017. PMID: 27659429 Review.
1,006 results